Michael Leek, PhD, on Manufacturing Challenges in Cell Therapy

Video

The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.

"If cell therapies became mainstream, and there were 20, 30, 40 cell therapies being worked on in every center of excellence, they can't all have different freeze-thaw processes. So there has to be a degree of unification going forward in how we ship product to the clinic, how we thaw the product to make sure it's still viable, and how we then get it into the patient, either through a drip or through direct injection. Those end point questions around delivery to the patient are really important and we haven't really fully addressed those yet."

As the cell therapy industry continues to grow, companies, organizations, and healthcare professionals continue to encounter challenges in the processes of manufacturing, shipping, and ultimate delivery to patients.

Michael Leek, PhD, co-founder and executive chairman of TC BioPharm, presented on the manufacturing challenges and regulatory, logistics, and quality hurdles in cell therapy development at the Onco Cell Therapy Summit (OCTS) USA 2022, held June 29-30 in Boston, Massachusetts.

CGTLive spoke with Leek to learn more about his insights from 35 years of experience in the cell therapy space. He emphasized the importance of having control over the manufaturing process and of developing universal standards for the industry, and discussed future potential applications for cell therapies as the field continues to advance.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.